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Abstract
We present our retrospective study of 42 patients treated for hepatic oligorecurrence with stereotactic body
radiotherapy using the CyberKnife system (Accuray Inc). Besides reporting on acute and late toxicities, the
inﬂuence of patient and lesion characteristics on local control, liver and distant progression-free survival, and
overall survival were also investigated.
Background: The purpose of this study was to analyze local control (LC), liver progression-free survival (PFS), and
distant PFS (DFS), overall survival (OS), and toxicity in a cohort of patients treated with stereotactic body radiotherapy
(SBRT) with ﬁducial tracking for oligorecurrent liver lesions; and to evaluate the potential inﬂuence of lesion size,
systemic treatment, physical and biologically effective dose (BED), treatment calculation algorithms and other
parameters on the obtained results. Patients and Methods: Unoperable patients with sufﬁcient liver function had
[18F]-ﬂuorodeoxyglucose-positron emission tomography-computed tomography and liver magnetic resonance
imaging to conﬁrm the oligorecurrent nature of the disease and to further delineate the gross tumor volume (GTV). An
intended dose of 45 Gy in 3 fractions was prescribed on the 80% isodose and adapted if risk-related. Treatment was
executed with the CyberKnife system (Accuray Inc) platform using ﬁducials tracking. Initial plans were recalculated
using the Monte Carlo algorithm. Patient and treatment data were processed using the KaplaneMeier method and log
rank test for survival analysis. Results: Between 2010 and 2015, 42 patients (55 lesions) were irradiated. The mean
GTV and planning target volume (PTV) were 30.5 cc and 96.8 cc, respectively. Treatments were delivered 3 times per
week in a median of 3 fractions to a PTV median dose of 54.6 Gy. The mean GTV and PTV D98% were 51.6 Gy and
51.2 Gy, respectively. Heterogeneity corrections did not inﬂuence dose parameters. After a median follow-up of 18.9
months, the 1- and 2-year LC/liver PFS/DFS/OS were 81.3%/55%/62.4%/86.9%, and 76.3%/42.3%/52%/78.3%,
respectively. Performance status and histology had a signiﬁcant effect on LC, whereas age (older than 65 years)
marginally inﬂuenced liver PFS. Clinical target volume physical dose V45 Gy > 95%, generalized equivalent uniform
dose (a ¼ 30) > 45 Gy and a BED (a/b ¼ 10) V105 Gy > 96% showed statistically signiﬁcant effect on the LC. Acute
Grade 3 gastrointestinal (GI) and late Grade 2 GI and fatigue toxicity were found in 5% and 11% patients, respectively.
Conclusion: Favorable survival and toxicity results support the potential paradigm shift in which the use of SBRT in
oligorecurrent liver disease could beneﬁt patients with unresectable or resectable liver metastases.
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The most common metastatic lesion to the liver is from
colorectal origin.1 Approximately 50% of colorectal cancer
(CRC) patients will be diagnosed with either synchronous or
metachronous liver metastasis.2,3 Without treatment, the 3-year
survival rates remain dismal at 3%.4,5 The standard treatment
for hepatic oligometastasis is surgical resection,6,7 with aClinical Colorectal Cancer December 2017 - 349
350 -
SBRT for Unresectable Hepatic Oligorecurrencepotential curative intent and 5-year survival rates of 25% to
50% and 10-year overall (OS) up to 22% to 43%.8,9 Despite
improved surgical techniques,10 only a small (approximately
25%) proportion of patients with hepatic oligometastases are
eligible for surgical resection mainly because of medical or
technical contraindications.11 Over the past years, other local
treatment options have emerged such as embolization,12 thermic
ablation, and radiotherapy. These techniques improve long-term
tumor control and progression-free survival in case of inoperable
disease, but data on OS beneﬁt are scarce.13-19 Stereotactic body
radiotherapy (SBRT) allows delivery of focal ablative doses to
the hepatic metastases while sparing the normal hepatic tissue
and surrounding organs at risk.20,21 Numerous studies have now
conﬁrmed the feasibility, low toxicity, and efﬁcacy of such
treatments.22,23 In case of limited metastatic disease (up to 5
metastatic lesions), local control (LC) varies between 62% and
up to 92% and OS rates between 30% (2-year) and 72%
(1-year) with low rates of Grade 3 toxicity.8,24-26 The challenge
of SBRT to deliver high radiation doses to the liver is to
manage respiratory movements. Various breathing control stra-
tegies such as respiratory gating and motion management
techniques have been implemented to overcome this limita-
tion,27 including the CyberKnife system (Accuray Inc), which
performs real-time tumor tracking. This allows for a high level
of precision while treating the patient in free breathing and still
maintaining patient comfort. The primary aim of our retro-
spective study was to report on LC, liver and distant
progression-free survival, and OS of patients treated for pure
hepatic oligorecurrence (as deﬁned by Niibe and Hayakawa28)
with SBRT using the CyberKnife system, including the
observed acute and late toxicity.
Patients and Methods
Between September 2010 and July 2015 consecutive patients with
up to 3 synchronous liver metastases were included in this study for
CyberKnife treatment at the Liege University Hospital. All patients
were referred for stereotactic treatment after a full staging including
baseline registration of the liver function, chest and abdominal diag-
nostic computed tomography (CT) and hepatic magnetic resonance
imaging (MRI) or [18F]-ﬂuorodeoxyglucose (FDG) positron emis-
sion tomography (PET)-CT imaging, conﬁrming the absence of tu-
moral activity at the primary tumor site and extrahepatic metastases.
Patients were informed of the intent, side effects, and practical mo-
dalities of the treatment and consent for treatment was obtained
before SBRT. All patients were considered unsuitable candidates for
surgical resection.We included lesions in any locationwithin the liver,
irrespective of previous treatments including chemotherapy, surgery,
or other local treatments such as previous radiotherapy for meta-
chronous hepatic metastases. Patients with heavily compromised liver
function tests (ie, Child-Pugh class C, platelet count <60  109/L
and hemoglobin <8 g/dL, and/or liver enzymes >3 times the upper
limit of normal), ascites, tumors >6 cm in diameter, uncontrolled
primary tumor, and patients with an expected life expectancy
of<6months were excluded from standard SBRT treatment. Grade 3
toxicity or Radiation Induced Liver Disease (RILD) were relative
exclusion criteria for reirradiation.Clinical Colorectal Cancer December 2017CyberKnife Planning and Treatment
All patients had radio-opaque 3-mm long gold ﬁducials
(Goldlock; Beampoint) placed using transabdominal puncture with
CT guidance by a dedicated interventional radiologist. The 3
intended ﬁducials were placed according to Accuray guidelines.
The treatment simulation took place at least 1 week later to avoid
marker migration between the simulation and the start of the
treatment. Patients were positioned in the supine position in a
vacuum bag (Orﬁt), using a knee and feet support system with
arms next to the body. A multislice CT scan was obtained with a
slice thickness of 1 mm using a CT simulator (Brilliance BigBore
CT scan, Philips). After the ﬁrst scan series in mild expiration, a
second scan was obtained after intravenous iodine-based contrast
injection. Additional PET-CT imaging was obtained in the treat-
ment position, using the same immobilization devices followed by
liver MRI, without the vacuum bag. All Digital Imaging and
Communications in Medicine image series were rigidly coregis-
tered using the Multiplan treatment planning system (Accuray,
Inc) with special attention with regard to proper matching on the
ﬁducials. During treatment planning the following organs at risk
were delineated: left and right lung, esophagus, heart, thoracic wall
or ribs, left and right kidneys, intestinal structures, stomach, spinal
canal, whole liver, great vessels, and a 4-mm skin area.
A gross tumor volume (GTV) was deﬁned on the expiration
reference CT scan, using mutual information from all available
fused images. A clinical target volume (CTV) margin of 5 mm was
added and manually corrected in function of liver capsule and
adjacent structures. A uniform 3-mm margin was used to create the
planning target volume (PTV). For most of the patients, the
intended prescription dose was 45 Gy in 3 fractions to the 80%
isodose line. Aimed PTV coverage was 95% with the prescription
dose. In case of reirradiation, former treatment plans were taken
into account by either using the previous isodose lines for the
optimization purpose (before December 2014) or proper physical
dose summation of irradiation(s) with the actual plan (after
December 2014) using Mirada RTx (version 1.6.2/1.6.2, Mirada
Medical). The organs at risk dose constraints reported by Tim-
merman29 were always respected, at cost of altered fractionation and
if required, sacriﬁcing the target coverage. The estimated fraction
duration was kept in all cases <70 minutes. The treatment was
delivered using a CyberKnife VSI system with Robocouch and
planned using Multiplan treatment planning software with
Raytracing algorithm (version 4.6, Accuray). The treatment plan
was retrospectively recalculated using a Monte Carlo (MC) dose
calculation algorithm (version 5.1), to evaluate the potential effect
on the dose distribution of using equivalent path length heteroge-
neity correction algorithm in the lung vicinity. Synchrony
Respiratory Tracking System was used to continuously track ﬁducial
position and synchronize beam delivery with respiratory motion.
Tracking was ideally performed on all available ﬁducials but was
adapted in case of suboptimal ﬁducial visibility. The treatment
duration was recorded and the treatment sessions were each deliv-
ered at an interval of a minimum of 40 hours. Patients were pre-
scribed proton pump inhibitors, serotonin 5-hydroxytryptamin
antagonists, benzodiazepines, and antacids in function of the
symptomatology.







Female 19 (45.2) 25 (46.3)
Male 23 (54.8) 29 (53.7)
Median Age at SBRT
(Range), y
67.1 (43.1-83.3) 68.4 (43.1-83.3)
Median Age at Diagnosis
(Range), y
66.9 (42.5-83) 67.9 (42.5-83)
Primary Site, n (%)
Colorectal 25 (59.5) 30 (55.6)
Breast 7 (16.7) 11 (20.4)
Other 5 (11.9) 6 (11.1)
Lung 3 (7.1) 3 (5.6)
Stomach 1 (2.4) 2 (3.7)
Unknown 1 (2.4) 1 (1.9)
Melanoma 1 (2.4) 1 (1.9)
Lesion Treated at the Same
Time (on the Same
Computed Tomography
Scan), n (%)
1 32 (76.2) e
2 8 (19) e
3 2 (4.8) e
Performance Status,
n (%)
0 20 (47.6) 25 (46.3)
1 22 (52.4) 29 (53.7)
Previous Local Treatment,
n (%)
No 26 (61.9) 31 (57.4)
Surgery 11 (26.2) 15 (27.8)
Radiofrequency 10 (23.8) 12 (22.2)
Radiotherapy 5 (11.9) 5 (9.3)
Previous Chemotherapy,
n (%)
Yes 35 (83.3) 43 (79.6)
No 7 (16.7) 11 (20.4)
Patrick Berkovic et alFollow-up and Toxicity Evaluation
Patients were evaluated after the last fraction, at 2 weeks, and
then in function of the referring team at an interval of 2 to 4
months. At each outpatient contact a clinical examination and the
treatment toxicity was assessed. Treatment response was evaluated
using serial contrast enhanced spiral CT or MRI scans and was
deﬁned according to the Response Evaluation Criteria in Solid
Tumors version 1.1.30 LC was deﬁned as complete response (CR),
partial response (PR), or stable disease. Additional metachronous
liver lesions were scored as liver-speciﬁc progression. Toxicity was
evaluated using the Common Terminology Criteria for Adverse
Events version 4.0.31 Toxicities occurring 3 months after SBRT
were considered acute whereas toxicities occurring after 3 months
were considered late.
Data Analysis
Local control, liver progression free-survival (PFS), distant PFS
(DFS), and overall survival (OS) curves were evaluated using the
KaplaneMeier method. All data for LC were determined for each
lesion separately, whereas the liver PFS, DFS, and OS per patient
originated from the day of the ﬁrst SBRT treatment. Survival-
related subgroup analysis was performed using the log rank test.
For LC, additional investigation included treatment planning-
related parameters such as number of fractions, target volumes,
physical, and biological effective dose (BED; BED 10 considering
a/b ¼ 10) coverage and generalized equivalent uniform dose
(gEUD, a ¼ 30) for CTV and PTV in a systematic manner. For
all tests, a P value < .05 was considered as statistically signiﬁcant
using Python packages (Pandas version 0.15.2, Scipy version 0.14.0,
and Lifelines version 0.9.0.0).32
Results
During the period from September 2010 to September 2015, a
total of 42 patients with 55 lesions were irradiated in 48 treatments.
Eight and 2 patients were treated for, respectively, 2 and 3 syn-
chronous lesions. Pretreatment PET-CT and MRI was available for
all patients. A median of 3 (range, 2-5) ﬁducials was inserted.
Further population and tumor characteristics are presented in
Table 1.
Treatment Characteristics
The mean GTV and PTV were 30.5 cc (SD, 26.3) and 96.8 cc
(SD, 59.6), respectively. All treatments were delivered 3 times per
week in a median of 3 fractions (range, 3-6) to an average PTV
median dose of 54.6 Gy (range, 29.1-58.9). This corresponds to an
average median PTV BED 10 of 132 Gy (range, 57.5-174.76). The
mean GTV and PTV D98% were 51.6 Gy (SD, 6.2) and 51.2 Gy
(SD, 6.6), respectively. Dosimetric parameters are presented in
Table 2. Each treatment was delivered by an average of 137
(range, 63-224) beams and had an average duration of 41 minutes
(range, 24-68 minutes). All dose constraint parameters reported by
Timmerman were respected and the dose to 700 cc of uninvolved
liver tissue was consistently kept at <15 Gy. Retrospective recal-
culation with the MC algorithm showed a deviation of 0.3%
mean dose for target volumes (range, 1.7% to 2.1%), whereas for
all organs at risk was 1.7% (range, 7.5% to 2.2%) compared
with the Raytracing algorithm. These differences were consideredclinically irrelevant using MC either with ﬁducial-induced artifacts
(native CT) or with water equivalent liver (density overwrite)
leading to a target mean dose difference <1%.
Treatment Efﬁcacy
A post-treatment evaluation scan was available for all of the
treated lesions. Of the 55 treated lesions, 22 lesions (40.7%) were
deﬁned as a CR, 14 (25.9%) as a PR, and 8 (14.8%) lesions were
stable, whereas 10 lesions (18.5%) progressed. A typical CR on the
basis of before and follow-up FDG PET/CT is presented in
Figure 1. After a median follow-up of 18.9 months (range, 3.2-
50.4), the 1- and 2-year LC was 81.3% and 76.3%, respectively,
which remained stable thereafter. The corresponding liver PFS and
DFS rates were 55.0% and 42.3%, and 62.4% and 52.0%,
respectively. Associated OS rates were 86.9% and 78.3%, respec-
tively (Figure 2). Performance status (0 vs. 1þ) and histologyClinical Colorectal Cancer December 2017 - 351








Complete remission 22 (40.7)
Partial remission 14 (25.9)
Stable disease 8 (14.8)
Progressive disease 10 (18.5)
Mean Volume (SD)
Gross tumor volume 30.6 (26.3)
Clinical target volume 67.6 (48.2)
Planning target volume 96.9 (59.6)
Mean Treatment Executions (SD)
Beams, n 137 (38)
Treatment time, min 44.1 (10.9)
Mean OAR Dose Constraints (SD)
Spinal cord
D 1.0 mL 5.8 (3.1)
D 0.25 mL 6.3 (3.3)
D max 6.9 (3.6)
Esophagus
D 5.0 mL 3.7 (3.8)
Dmax 7.8 (7)
Heart
D 15.0 mL 7.2 (6.1)
Dmax 13.5 (10.2)
Great vessels
D 10.0 mL 8.6 (6.2)
Dmax 16.3 (11.1)
Stomach
D 10.0 mL 8.9 (4.7)
Dmax 14.3 (7.5)
Duodenum
D 5.0 mL 13 (5.2)
Dmax 21.1 (9.3)
Lungs
D 1500.0 mL 1.6 (0.9)
D 1000.0 mL 2.6 (1.4)
Liver
D 700.0 mL 7.8 (5.6)
Renal cortex
D 200.0 mL 3.1 (2.6)
Abbreviations: D“X” ¼ dose to the corresponding “X” volume of a given organ;
Dmax ¼ maximum dose of the organ; OAR ¼ organs at risk; RECIST ¼ Response Evaluation
Criteria In Solid Tumors.
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352 -(adenocarcinoma vs. other) showed a statistically signiﬁcant effect
on LC (Figure 3). All other parameters did not appear to change
signiﬁcantly time-related outcomes (Table 3; Supplemental Figure 1Clinical Colorectal Cancer December 2017in the online version). Target volumes and number of fractions did
not signiﬁcantly change LC. For CTV, a physical dose coverage of
45 Gy to at least 95% of the volume, at least a 45 Gy gEUD
(a ¼ 30) and a BED coverage (a/b ¼ 10) of 105 Gy to at least
96% of the volume showed a statistically signiﬁcant effect on LC.
Similar to PTV, were 95% volume coverage >43 Gy, 40 Gy gEUD
(a ¼ 30), and 98% > 85 Gy BED 10 considered a critical
threshold for the outcome measures.
Toxicity
No toxicities were observed during or after ﬁducial placement.
The SBRT treatment was well tolerated with observed acute
toxicities ranging from Grade 1 to 2 with an absolute rate of acute
Grade 3 gastrointestinal (GI) toxicity in 3 treatments (5%)
including 1 case of RILD. Late toxicities also remained mild with
6 (11%) observed Grade 2 GI (n ¼ 4) and fatigue (n ¼ 2). One
patient was hospitalized for investigation and intravenous treat-
ment because of GI toxicities (colic) and 1 patient died 10 months
after SBRT after GI hemorrhage. The treatment plan of this
patient was extensively analyzed and all treatment parameters and
constrains were well below tolerance. The patient had various
comorbidities including type 2 diabetes, Grade 2 esophagitis,
hypertension, and was treated with aspirin for a previous cardiac
event.
Discussion
Liver metastasis from solid tumors, particularly from primary
CRC, represent an important clinical challenge. If left untreated the
prognosis is poor with a median survival of <1 year.9 In case of
multiple liver metastases, chemotherapy remains the mainstay of the
treatment.7 However, if oligometastatic disease is diagnosed,
metastasis-directed local treatments might be considered.8,25
Numerous studies have shown the efﬁcacy and survival beneﬁt of
surgical resection with a median survival between 40 and 64
months.9 Unfortunately, most patients are found to be either sur-
gically or medically unoperable. In recent years, radiotherapy has
emerged as an effective and well tolerated treatment for patients
with liver metastasis. Using modern stereotactic technology,
including MRI and PET/CT imaging for accurate tumor delinea-
tion, intensity modulated radiotherapy and image-guided radio-
therapy technology including tumor tracking for accurate treatment
delivery, it has become the current standard in unresectable liver
metastases treatment.22
Local Control
We report on 42 patients with 55 liver metastases, mostly from
primary CRC, treated with a CyberKnife system with a median
follow-up of 18.9 months. Our 1- and 2-year LC rates of approx-
imately 80% are comparable with previously published data
describing a cohort of liver metastasis only.9 In fact, numerous
studies have consistently shown the deleterious effect of previous
chemotherapy, probably because of possible selection of radio-
resistant cells, and worst LC rates of liver metastases from colorectal
origin. Our study concurs with the latter data in a subgroup anal-
ysis, besides performance status, colorectal adenocarcinoma had a
statistically signiﬁcant worst LC than other histologies.1,33 How-
ever, we could not conﬁrm a signiﬁcant effect on LC in our heavily
Figure 1 Pretreatment Fused Positron Emission Tomography (PET)-Computed Tomography (CT) (Left) Shows the CyberKnife Highly
Conformal Dose Distribution Targeted at the PET-Hypermetabolism Region, Gross Tumor Volume (Red), Using Fiducials
(Black Arrow) Tracking. The 11-month Post-treatment (Right) PET-CT Shows No Hyperactivity Within the Liver, Indicating a
Complete Remission
Patrick Berkovic et alpretreated cohort in which, in fact, 80% received chemotherapy
before SBRT. Moreover, in contrast to previous publications, we
could not ﬁnd any signiﬁcant correlation between GTV size and
LC.34 Despite the extensive use of SBRT in the oligometastatic
setting, the precise radiobiology and cell-killing effects of this
hypofractionated schedules have not been fully understood.
Numerous studies have shown a dose response for LC but there is
still uncertainty on the optimal threshold dose. We addressed this
particular issue and suggest a prescription threshold dose of 45 Gy
on the CTV and >43 Gy on the PTV to at least 95% of both
volumes to signiﬁcantly improve LC. This dose is on the lower end
of the recommended prescription dose of 48 Gy in 3 fractions
described in the review report by Høyer et al.22 However, this
recommendation is on the basis of heterogeneous studies with very
different tumor histologies and fraction sizes ranging from 1 to 6
fractions. In a pooled analysis by Chang et al,34 a similar dose
response is observed with a required prescription dose of 46 to 52
Gy in 3 fractions to achieve a 90% LC. Rusthoven et al26 observed
LC rates >90% with a fractionation schedule of 3 fractions of 20
Gy. In contrast, Takeda et al35 improved the LC rates by increasing
the dose to the lesion up to 83 till 100 Gy maximum dose with the
prescribed dose of 50 to 60 Gy in 5 fractions on the 60% isodose to
encompass the PTV. By using BED to account for different dose
fractionation schedules, we observed a signiﬁcant effect on LC for aBED of 105 Gy to at least 95% of the volume, again, lower than the
117 Gy proposed by Chang et al34 to achieve 90% LC.
Liver PFS
The only factor shown to marginally correlate with liver PFS was
the age of the patient (older or younger than 65 years, with
P ¼ .07). In our experience the 1- and 2-year liver PFS was 55%
and 42.3%, respectively. Our high rates, compared with the
literature, are despite that our population was heavily pretreated.9
Overall Survival
Despite the selection bias of our patient population with most
patients classiﬁed according to the World Health Organization as 1
with several comorbidities, who were considered clinically inoper-
able, our 1- and 2-year OS rates were 86.9% and 78.3%, respec-
tively. These numbers are at the higher end compared with the
recent SBRT literature with 1-year OS rates between 67% and
85%.8,24,25 Compared with the surgical resection series and tumor
ablation series our data are also at the higher end with 1-year OS
rates in the range between 71% and 93% for surgery and 71% to
88% for tumor ablation.11 Although LC rates have been shown in
previous studies to be a key determinant of OS, our high OS rates
are probably because of our rigid inclusion criteria. All of our pa-
tients were (PET-CT conﬁrmed) exclusively oligorecurrent in theClinical Colorectal Cancer December 2017 - 353
Figure 2 KaplaneMeier Curves and Log-Rank Test for Local Control, Liver Progression-free Survival (PFS), Disease-free Survival, and
Overall Survival for Patient-related Parameters
Abbreviation: Adenocc ¼ adenocarcinoma.
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354 -liver with the absence of tumoral activity at the primary site ac-
cording to the concept proposed by Niibe and Hayakawa.28
Toxicity
Despite our relatively large PTVs (mean¼ 96.9 cc, SD¼ 59.6 cc)
we observed only 3 Grade 3 GI toxicities. One case of RILD was
reported, which subsided after conservative treatment. One patient
with late Grade 3 toxicities was observed and 1 patient died 10
month after SBRT treatment, probably because of his numerous
comorbidities. None of our patients developed signs of liver failure or
jaundice. These observations are in line with previously published
low toxicity rates after CyberKnife treatment.1,36,37 Consistently
respecting the liver constraint parameters whereby not less than
700 cc of uninvolved liver tissue received more than 17.1 Gy in
3 fractions, along with the vacuum bag and the precision of the
CyberKnife Synchrony tracking system, which allowed the delivery
of high doses to the lesion while safeguarding the liver function. This
allowed us to treat most of our patients (30 [72.2%] out of 42) with
the intended higher BED prescription of 3 fractions of 15 Gy
compared with the other risk-adapted fractionation schemes.
Furthermore, we observed no toxicity besides mild chest wall pains
after ﬁducial placement.Clinical Colorectal Cancer December 2017Similar to Swaminath et al,38 we found a direct effect of the target
volume coverage on the basis of the treatment planning parameters
and LC, showing that the intended prescribed dose alone does not
guarantee the effectiveness of the treatment. In their study patients
were treated using Linac-based SBRT and four dimensional com-
puter tomography approach and the accumulated GTV and mini-
mum PTV dose was determined according to deformable dose
accumulation (on the basis of 2-dimensional projections). Using
CyberKnife with real-time tumor tracking, the physical, biological,
and gEUD dose on the PTV and CTV with certain thresholds
resulted as relevant. On the basis of these results, one might
conclude that treatments for which sufﬁcient target coverage cannot
be achieved need to be reconsidered, because without reaching
certain levels on dose delivery, the added value of local SBRT is not
guaranteed for LC.
Limitations
Limitations of the current study include the retrospective nature
and themild variation in treatment schedules and delivered doses. The
variability and quantity of previous chemotherapy schedules might
also bias our LC and OS rates because of possible selection of radio-
resistant cells.39 Furthermore, no control group was available to
Figure 3 KaplaneMeier Curves and Log-Rank Test for Local Control With Treatment-related Parameters
Abbreviations: BED ¼ biological effective dose; CTV ¼ clinical target volume; gEUD ¼ generalized equivalent uniform dose; GTV ¼ gross tumor volume; PTV ¼ planning target volume; V“X” ¼
volume covered by the dose of “X” Gy.
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356 - Clinical Colorectal Cancer December 2017compare SBRT with other local treatment modalities including
transcatheter arterial chemoembolization, radiofrequency ablation, or
surgery. The patients were referred to and later followed in different
institutions, so no standardized imaging protocols were used. Finally,
longer patient follow-up would enable us to report more accurately on
the interaction between delivered dose, LC, and OS.
Conclusion
We present data of 42 patients treated for 55 unresectable
hepatic-only oligometastasis with controlled primary disease using
the CyberKnife system. Our data are encouraging with outcome
numbers at the higher end of the SBRT literature regarding LC and
OS and comparable with the OS data for surgical and tumor
ablation series. Most of our patients were treated in 3 fractions of 15
Gy with low toxicity rates. We propose a prescription threshold dose
of 45 Gy on the CTV and >43 Gy on the PTV to at least 95% of
both volumes to signiﬁcantly improve LC. Our results support the
potential paradigm shift whereby the use of SBRT in truly oligo-
metastatic (ie, oligorecurrent) liver disease could beneﬁt patients
with liver metastases. However, longer follow-up is required espe-
cially concerning patient selection and fractionation schedules, to
effectively determine the position of SBRT relative to surgical
resection and other invasive techniques.
Clinical Practice Points
 Oligorecurrent liver metastases are frequently encountered in
oncology and are associated with an unfavorable prognosis if
untreated (3-year survival rate of approximately 3%).
 Surgical resection as standard of care potentially increase the
10-year OS up to 22% to 43%, however, only one-quarter of the
patients are eligible for such treatment.
 Other possible localized treatments are embolization, thermic
ablation, and radiotherapy.
 A special form of radiotherapy (eg, SBRT) showed a potential
increase of LC, but OS data are scarce.
 Using robotic SBRT with tumor tracking capacity (eg, the
CyberKnife platform) might further improve clinical outcome.
 Clinical factors such performance status and histology inﬂuences
LC, whereas age tends to affect liver-speciﬁc PFS.
 Using CyberKnife with real-time tumor tracking, biological
treatment planning parameters (dose volume limits to target
volumes) with certain minimum thresholds are crucial.
Disclosure
The authors report no conﬂicts of interest. The authors alone are
responsible for the content and writing of the paper.
Supplemental Data
Supplemental ﬁgure accompanying this article can be found in
the online version at http://dx.doi.org/10.1016/j.clcc.2017.03.006.References
1. Yuan ZY, Meng MB, Liu CL, et al. Stereotactic body radiation therapy using the
CyberKnife system for patients with liver metastases. Onco Targets Ther 2014; 7:
915-23.
2. Bengmark S, Hafström L. The natural history of primary and secondary malignant
tumors of the liver. I. The prognosis for patients with hepatic metastases from
colonic and rectal carcinoma by laparotomy. Cancer 1969; 23:198-202.
Patrick Berkovic et al
3. Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases.
Clin Colon Rectal Surg 2009; 1:225-32.
4. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following
liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759-66.
5. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural
history of hepatic metastases from colorectal cancer. A comparison with resective
treatment. Ann Surg 1984; 199:502-8.
6. Akgül Ö, Çetinkaya E, Ersöz S¸, Tez M. Role of surgery in colorectal cancer liver
metastases. World J Gastroenterol 2014; 20:6113-22.
7. Van Cutsem E, Nordlinger B, Cervantes A, ESMO Guidelines Working Group.
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann
Oncol 2010; 21(suppl 5):v93-7.
8. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset
of metastases curable with stereotactic radiotherapy. J Clin Oncol 2013; 31:1384-
90.
9. Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cárdenes HR. Long-
term safety and efﬁcacy of stereotactic body radiation therapy for hepatic oligo-
metastases. Pract Radiat Oncol 2015; 6:86-95.
10. Lemke J, Cammerer G, Ganser J, et al. Survival and prognostic factors of colorectal
liver metastases after surgical and nonsurgical treatment. Clin Colorectal Cancer
2016; 15:e183-92.
11. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A. Frameless
single-session robotic radiosurgery of liver metastases in colorectal cancer patients.
Eur J Cancer 2010; 46:1026-32.
12. Kennedy AS, Ball DS, Cohen SJ, et al. Safety and efficacy of radioembolization in
elderly ( 70 years) and younger patients with unresectable liver-dominant colo-
rectal cancer. Clin Colorectal Cancer 2016; 15:141-151e6.
13. Yoon SS, Tanabe KK. Surgical treatment and other regional treatments for colo-
rectal cancer liver metastases. Oncologist 1999; 4:197-208.
14. Stintzing S, Grothe A, Hendrich S, et al. Percutaneous radiofrequency ablation
(RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver me-
tastases. Acta Oncol 2013; 52:971-7.
15. Ravikumar TS. Interstitial therapies for liver tumors. Surg Oncol Clin N Am 1996;
5:365-77.
16. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation
of hepatic metastases from colorectal cancer: long-term results in 117 patients.
Radiology 2001; 221:159-66.
17. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I. Comparison of resection
and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br
J Surg 2003; 90:1240-3.
18. Dawson LA. Overview: where does radiation therapy ﬁt in the spectrum of liver
cancer local-regional therapies? Semin Radiat Oncol 2011; 21:241-6.
19. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded
drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic
metastases from colorectal cancer: ﬁnal results of a phase III study. Anticancer Res
2012; 32:1387-95.
20. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat
Oncol 2011; 21:264-70.
21. Wulf J, Hädinger U, Oppitz U, Thiele W, Flentje M. Stereotactic boost irradiation
for targets in the abdomen and pelvis. Radiother Oncol 2004; 70:31-6.22. Høyer M, Swaminath A, Bydder S, et al. Radiotherapy for liver metastases: a
review of evidence. Int J Radiat Oncol Biol Phys 2012; 82:1047-57.
23. Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost effectiveness
analysis of stereotactic body radiation therapy compared with radiofrequency
ablation for inoperable colorectal liver metastases. Int J Radiat Oncol 2016; 95:
1175-83.
24. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for
oligometastases. Lancet Oncol 2013; 14:e28-37.
25. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin
Oncol 2014; 32:2902-12.
26. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II
trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;
27:1572-8.
27. Boda-Heggemann J, Dinter D, Weiss C, et al. Hypofractionated image-guided
breath-hold SABR (stereotactic ablative body radiotherapy) of liver meta-
staseseclinical results. Radiat Oncol 2012; 7:92.
28. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer
therapy. Jpn J Clin Oncol 2010; 40:107-11.
29. Timmerman RD. An overview of hypofractionation and introduction to this issue
of seminars in radiation oncology. Semin Radiat Oncol 2008; 18:215-22.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria In
Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:
228-47.
31. US Department of Health and Human Services. Common terminology criteria
for adverse events (CTCAE) version 4.0. Bethesda, MD: National Cancer
Institute. 2009 (09-5410).
32. McKinney W. Data structures for statistical computing in python. In: van der
Voort S, Millman J, eds. Proceedings of the 9th Python in Science Conference, Vol.
445. Austin, TX: SciPy; 2010:51-6.
33. Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between
metastases based on primary histology suggest implications for clinical outcomes
follwoing SBRT. Int J Radiat Oncol Biol Phys 2016; 95:1399-404.
34. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for
colorectal liver metastases: a pooled analysis. Cancer 2011; 117:4060-9.
35. Takeda A, Sanuki N, Tsurugai Y, Oku Y, Aoki Y. Stereotactic body radiotherapy
for patients with oligometastases from colorectal cancer: risk-Adapted dose pre-
scription with a maximum dose of 83-100 Gy in ﬁve fractions. J Radiat Res 2016;
57:400-5.
36. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A.
Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver
tumors. Ann Surg Oncol 2010; 17:2877-83.
37. Sanabria J, Goyal K, Einstein D, et al. Cyberknife stereotactic body radiation
therapy for nonresectable tumors of the liver: preliminary results. HPB Surg 2010;
2010:309780.
38. Swaminath A, Massey C, Brierley JD, et al. Accumulated delivered dose response
of stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol
Phys 2015; 93:639-48.
39. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation
therapy for primary and metastatic liver tumors: a single institution phase I-II
study. Acta Oncol 2006; 45:831-7.Clinical Colorectal Cancer December 2017 - 357
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